386 related articles for article (PubMed ID: 33923363)
1. Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups.
Rammensee HG; Gouttefangeas C; Heidu S; Klein R; Preuß B; Walz JS; Nelde A; Haen SP; Reth M; Yang J; Tabatabai G; Bösmüller H; Hoffmann H; Schindler M; Planz O; Wiesmüller KH; Löffler MW
Vaccines (Basel); 2021 Apr; 9(5):. PubMed ID: 33923363
[TBL] [Abstract][Full Text] [Related]
2. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
Rammensee HG; Wiesmüller KH; Chandran PA; Zelba H; Rusch E; Gouttefangeas C; Kowalewski DJ; Di Marco M; Haen SP; Walz JS; Gloria YC; Bödder J; Schertel JM; Tunger A; Müller L; Kießler M; Wehner R; Schmitz M; Jakobi M; Schneiderhan-Marra N; Klein R; Laske K; Artzner K; Backert L; Schuster H; Schwenck J; Weber ANR; Pichler BJ; Kneilling M; la Fougère C; Forchhammer S; Metzler G; Bauer J; Weide B; Schippert W; Stevanović S; Löffler MW
J Immunother Cancer; 2019 Nov; 7(1):307. PubMed ID: 31730025
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 spike protein-derived immunogenic peptides that are promiscuously presented by several HLA-class II molecules and their potential for inducing acquired immunity.
Yajima Y; Kosaka A; Ohkuri T; Hirohashi Y; Li D; Nagasaki T; Nagato T; Torigoe T; Kobayashi H
Heliyon; 2023 Sep; 9(9):e20192. PubMed ID: 37809871
[TBL] [Abstract][Full Text] [Related]
4. Landscape and selection of vaccine epitopes in SARS-CoV-2.
Smith CC; Olsen KS; Gentry KM; Sambade M; Beck W; Garness J; Entwistle S; Willis C; Vensko S; Woods A; Fini M; Carpenter B; Routh E; Kodysh J; O'Donnell T; Haber C; Heiss K; Stadler V; Garrison E; Sandor AM; Ting JPY; Weiss J; Krajewski K; Grant OC; Woods RJ; Heise M; Vincent BG; Rubinsteyn A
Genome Med; 2021 Jun; 13(1):101. PubMed ID: 34127050
[TBL] [Abstract][Full Text] [Related]
5. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
6. Identification of HLA-A*02:01-restricted candidate epitopes derived from the non-structural polyprotein 1a of SARS-CoV-2 that may be natural targets of CD8
Takagi A; Matsui M
J Virol; 2021 Mar; 95(5):. PubMed ID: 33268522
[TBL] [Abstract][Full Text] [Related]
7. HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gamma-secreting CD4+ and CD4+ /CD8+ T cells in humans after lipopeptide vaccination.
Gahery H; Figueiredo S; Texier C; Pouvelle-Moratille S; Ourth L; Igea C; Surenaud M; Guillet JG; Maillere B
AIDS Res Hum Retroviruses; 2007 Mar; 23(3):427-37. PubMed ID: 17411376
[TBL] [Abstract][Full Text] [Related]
8. Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination.
Taus E; Hofmann C; Ibarrondo FJ; Gong LS; Hausner MA; Fulcher JA; Krogstad P; Kitchen SG; Ferbas KG; Tobin NH; Rimoin AW; Aldrovandi GM; Yang OO
Front Immunol; 2023; 14():1100594. PubMed ID: 36860850
[TBL] [Abstract][Full Text] [Related]
9. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity.
Heitmann JS; Bilich T; Tandler C; Nelde A; Maringer Y; Marconato M; Reusch J; Jäger S; Denk M; Richter M; Anton L; Weber LM; Roerden M; Bauer J; Rieth J; Wacker M; Hörber S; Peter A; Meisner C; Fischer I; Löffler MW; Karbach J; Jäger E; Klein R; Rammensee HG; Salih HR; Walz JS
Nature; 2022 Jan; 601(7894):617-622. PubMed ID: 34814158
[TBL] [Abstract][Full Text] [Related]
10. Exosomal Vaccine Loading T Cell Epitope Peptides of SARS-CoV-2 Induces Robust CD8
Shen AR; Jin XX; Tang TT; Ding Y; Liu XT; Zhong X; Wu YD; Han XL; Zhao GY; Shen CL; Lv LL; Liu BC
Int J Nanomedicine; 2022; 17():3325-3341. PubMed ID: 35937077
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
12. A Peptide Vaccine Candidate Tailored to Individuals' Genetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects.
Somogyi E; Csiszovszki Z; Molnár L; Lőrincz O; Tóth J; Pattijn S; Schockaert J; Mazy A; Miklós I; Pántya K; Páles P; Tőke ER
Front Genet; 2021; 12():684152. PubMed ID: 34249101
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
[TBL] [Abstract][Full Text] [Related]
14. Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection.
Sedegah M; Porter C; Goguet E; Ganeshan H; Belmonte M; Huang J; Belmonte A; Inoue S; Acheampong N; Malloy AMW; Hollis-Perry M; Jackson-Thompson B; Ramsey KF; Alcorta Y; Maiolatesi SE; Wang G; Reyes AE; Illinik L; Sanchez-Edwards M; Burgess TH; Broder CC; Laing ED; Pollett SD; Villasante E; Mitre E; Hollingdale MR
PLoS One; 2022; 17(10):e0276241. PubMed ID: 36251675
[TBL] [Abstract][Full Text] [Related]
15. Detection of IFNγ-Secreting CD4
Matyushenko V; Isakova-Sivak I; Kudryavtsev I; Goshina A; Chistyakova A; Stepanova E; Prokopenko P; Sychev I; Rudenko L
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452355
[TBL] [Abstract][Full Text] [Related]
16. Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19.
Heide J; Schulte S; Kohsar M; Brehm TT; Herrmann M; Karsten H; Marget M; Peine S; Johansson AM; Sette A; Lütgehetmann M; Kwok WW; Sidney J; Schulze Zur Wiesch J
PLoS Pathog; 2021 Sep; 17(9):e1009842. PubMed ID: 34529740
[TBL] [Abstract][Full Text] [Related]
17. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients.
Fonseca SG; Coutinho-Silva A; Fonseca LA; Segurado AC; Moraes SL; Rodrigues H; Hammer J; Kallás EG; Sidney J; Sette A; Kalil J; Cunha-Neto E
AIDS; 2006 Nov; 20(18):2263-73. PubMed ID: 17117012
[TBL] [Abstract][Full Text] [Related]
19. Comparison between enzyme-linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS-CoV-2 after symptomatic COVID-19.
Villemonteix J; Cohen L; Guihot A; Guérin V; Moulin C; Caseris M; Carol A; Bonacorsi S; Carcelain G
Immun Inflamm Dis; 2022 Oct; 10(10):e617. PubMed ID: 36169252
[TBL] [Abstract][Full Text] [Related]
20. Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP).
Sedegah M; Kim Y; Ganeshan H; Huang J; Belmonte M; Abot E; Banania JG; Farooq F; McGrath S; Peters B; Sette A; Soisson L; Diggs C; Doolan DL; Tamminga C; Villasante E; Hollingdale MR; Richie TL
Malar J; 2013 Jun; 12():185. PubMed ID: 23738590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
